Tag Archive: PCI

Sep 07

The data has been presented at the European Society of Cardiology (ESC) 2014 Congress.

Two–year results from the FAME–2 study have shown that PCI is superior to medical therapy for the reduction of hard clinical end points in patients with stable coronary artery disease. Researchers stressed that PCI is superior to medical therapy as along as fractional flow reserve (FFR) is used to guide treatment decisions. The data has …

Continue reading »

Jul 28

The revised guidance from the National Institute for Health and Care Excellence (NICE)

The revised guidance from the National Institute for Health and Care Excellence (NICE) recommends once–daily, oral antiplatelet prasugrel, in combination with aspirin, as a cost–effective option in comparison to generic clopidogrel, for a wider group of acute coronary syndrome (ACS) patients having primary or delayed percutaneous coronary intervention (PCI).

Jul 21

The report has been published in BMJ

A new meta–analysis has suggested that medical therapy plus revascularization with PCI using newer–generation drug–eluting stents (DES) improves survival better than an initial strategy of optimal medical therapy (OMT) only. No such advantage was seen for PCI using either bare–metal stents or early–generation DES. The report has been published in BMJ.